SCHEMBL1004649

SCHEMBL1004649

CN(C)C(=O)c1ccc(C(=O)N(C)C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.73
HPGD P15428 4/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
ERN1 O75460 2/20 0.50
HSP90AA1 P07900 1/20 0.48
PDK2 Q15119 1/20 0.48
MAPT P10636 2/20 0.47
EPHX2 P34913 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
CYP3A4 P08684 3/20 0.46
KDM4E B2RXH2 2/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
HDAC4 P56524 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10626283 0.92 ALDH1A1 (0.64) ALDH1A1HPGDSMN1; SMN2ERN1PDK2
SCHEMBL469413 0.89 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2ERN1MEN1
SCHEMBL487487 0.89 HPGD (0.61) ALDH1A1HPGDSMN1; SMN2ERN1HSP90AA1
SCHEMBL949041 0.89 HPGD (0.61) ALDH1A1HPGDSMN1; SMN2ERN1HSP90AA1
SCHEMBL1300109 0.89 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2ERN1HSP90AA1
SCHEMBL458926 0.89 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2MEN1TP53
SCHEMBL24783913 0.87 ALDH1A1 (0.67) ALDH1A1HPGDSMN1; SMN2HSP90AA1PDK2
SCHEMBL9923439 0.87 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2ERN1HSP90AA1
SCHEMBL642860 0.87 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2ERN1MAPT
SCHEMBL2212261 0.87 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2ERN1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9878975-B2 Catalytic hydrogenation for producing amines from carboxylic acid amides, carboxylic acid diamides, di-, tri-, or polypeptides, or peptide amides EVONIK DEGUSSA GMBH (DE) 2018-01-30 US claimed
US-5338644-A Form complexes with N,N,N*,N*-tetrasubstituted diamides of aromatic dicarboxylic acids to prevent migration of hydroquinones puring storage POLAROID CORPORATION (US) 1994-08-16 US claimed
US-5177262-A Hydrogen-Bonded Complex with N,N,N',N'-Tetrasubstituted P-Aromatic Dicarboxamides POLAROID CORPORATION (US) 1993-01-05 US claimed
CN-111225940-B Polymerization process 杜邦聚合物公司 2023-10-10 CN disclosed
US-9878975-B2 Catalytic hydrogenation for producing amines from carboxylic acid amides, carboxylic acid diamides, di-, tri-, or polypeptides, or peptide amides EVONIK DEGUSSA GMBH (DE) 2018-01-30 US disclosed
US-20160272571-A1 Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides EVONIK DEGUSSA GMBH (DE) 2016-09-22 US disclosed
EP-3066065-A1 CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES Evonik Degussa GmbH (DE) 2016-09-14 EP disclosed
WO-2015067450-A1 CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES EVONIK INDUSTRIES AG (DE) 2015-05-14 WO disclosed
EP-2868643-A1 Catalytic hydrogenation for the preparation of amines from carboxylic acid amides, carboxylic acid amides, di-, tri- or polypeptides or peptide amides Evonik Industries AG (DE) 2015-05-06 EP disclosed
US-8778219-B2 Ionic liquids for separation of olefin-paraffin mixtures UT-BATTELLE, LLC (US) 2014-07-15 US disclosed
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AUSPEX PHARMACEUTICALS, INC. (US) 2014-04-17 US disclosed
EP-0523470-B1 Complexed hydroquinones POLAROID CORP (US) 1997-03-19 EP disclosed
EP-0496264-B1 Process for preparing 2,6-naphthalenedicarboxylic acid MITSUBISHI CHEM CORP (JP) 1995-11-29 EP disclosed
US-5338644-A Form complexes with N,N,N*,N*-tetrasubstituted diamides of aromatic dicarboxylic acids to prevent migration of hydroquinones puring storage POLAROID CORPORATION (US) 1994-08-16 US disclosed
EP-0523470-A2 Complexed hydroquinones POLAROID CORPORATION (US) 1993-01-20 EP disclosed
US-5177262-A Hydrogen-Bonded Complex with N,N,N',N'-Tetrasubstituted P-Aromatic Dicarboxamides POLAROID CORPORATION (US) 1993-01-05 US disclosed
US-5175352-A PROCESS FOR PREPARING 2,6-NAPHTHALENEDICARBOXYLIC ACID MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1992-12-29 US disclosed
EP-0518861-A1 PROCESS FOR OBTAINING PHOSPHOROUS ACID-BIS-(2,4-DI-TERT.-BUTYL-PHENYL) ESTER HALIDES. HOECHST AG (DE) 1992-12-23 EP disclosed
EP-0496264-A2 Process for preparing 2,6-naphthalenedicarboxylic acid Mitsubishi Chemical Corporation (JP) 1992-07-29 EP disclosed
WO-1991007415-A1 PROCESS FOR OBTAINING PHOSPHOROUS ACID-BIS-(2,4-DI-TERT.-BUTYL-PHENYL) ESTER HALIDES HOECHST AKTIENGESELLSCHAFT (DE) 1991-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PLA2G1B, PLA2G4A, PLA2G4B ALDH1A1 1423/4885HPGD 610/4885SMN1; SMN2 4141/4885
US-20160272571-A1 Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides DAO, DDC, HDGF ALDH1A1 2121/4885HPGD 1640/4885SMN1; SMN2 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.